


## CASE STUDY

James H. Holmes IV, MD, FACS / Wake  
Forest Baptist Medical Center, Winston  
Salem, NC


## PATIENT PRESENTATION

A 43-year-old male presented with a 19.5% total burn surface area (TBSA) mixed-depth flame burn. This case study focuses on RECELL treatment of the deep partial-thickness injury to the left lower leg using Spray-On Skin<sup>™</sup> Cells.



## CONCLUSION

*This case study demonstrates wound healing with the use of RECELL on a small deep partial-thickness burn. In this case, the use of autologous Spray-On Skin Cells alone resulted in a close match of natural skin coloring.*



## TREATMENT REGIMEN

This patient was treated as part of a prospective, observational study. Eleven days after the injury, the burn was excised (Figure A). Spray-On Skin Cells were prepared using the RECELL System and applied over the wound. The area was dressed with Telfa<sup>™</sup> Clear, followed by Xeroform<sup>™</sup> and outer bulky dressings.

## CLINICAL OUTCOME

On Day 7 post-RECELL treatment, the wound was fully re-epithelialized. Continued healing was apparent at Week 2 (Figure B). Close match of natural skin coloring was evident by Week 8 (Figure C). Further improvement in skin pigmentation was observed during follow-up at Week 16 (Figure D). By Week 52, the color and pigment of the treatment area exhibited a close match to the surrounding skin (Figure E).



INSIDE BURN PATIENTS' SKIN CELLS ARE  
REGENERATIVE FORCES AT THE READY.

**GIVE THEM THE SIGNAL TO MOVE.**

Visit [RECELLsystem.com](https://RECELLsystem.com) to learn more.

### IMPORTANT SAFETY INFORMATION

**INDICATIONS FOR USE:** The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds in patients 18 years of age and older. The RECELL® device is used by an appropriately licensed healthcare professional at the patient's point of care to prepare autologous RES® Regenerative Epidermal Suspension for direct application to acute partial-thickness thermal burn wounds or application in combination with meshed autografting for acute full-thickness thermal burn wounds.

**CONTRAINDICATIONS:** RECELL® is contraindicated for the treatment of wounds clinically diagnosed as infected or with necrotic tissue present in the wound bed. RECELL® is contraindicated for the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate solution (Hartmann's Solution). The skin sample collection procedure specified for use of RECELL® should not be used with patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.

**WARNINGS:** Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL® is provided sterile and is intended for single use. Do not use RECELL® or device components if packaging is damaged, there are signs of tampering or date of use is beyond the stated expiration date. Choose a skin sample

donor site that shows no evidence of surrounding cellulitis or infection. The skin sample should be processed immediately after harvesting. If a skin sample is harvested and processed according to these instructions, it should require between 15 and 30 minutes of contact with the Enzyme. Contact in excess of 60 minutes is not recommended. RECELL® Enzyme is animal derived and freedom from infectious agents cannot be guaranteed.

**PRECAUTIONS:** RECELL® is not intended to be used alone (i.e., without meshed autograft) for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL® used alone (i.e., without meshed autograft) have not been established for treatment of partial-thickness burn wounds: on the hands and articulated joints, >320 cm<sup>2</sup>, in patients with wounds totaling >20% Total Body Surface Area (TBSA). The safety and effectiveness of RECELL® plus autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, in patients with wounds totaling >50% Total Body Surface Area (TBSA).

**SPECIAL PATIENT POPULATIONS:** The safety and effectiveness of RECELL® have not been established for treatment of acute thermal partial-thickness or full-thickness burn wounds in pediatric patients younger than 18 years of age.

For complete Important Safety Information, refer to Instructions for Use at [RECELLSystem.com](https://RECELLSystem.com).